The cholesterol ester transfer protein inhibitor, anacetrapib (vol 22, pg 245, 2011)

被引：0
|
作者：
Jialal, I
Kaur, J.
机构：
来源：
CURRENT OPINION IN LIPIDOLOGY | 2011年 / 22卷 / 04期
关键词：
D O I：
10.1097/MOL.0b013e328348b6e5
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：326 / 326
页数：1
相关论文
共 50 条
  • [21] Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects
    Garg, Amit
    Maes, Andrea
    Corr, Christy
    Jin, Bo
    Wadhwa, Tarun
    Handa, Nikhil
    Van Dyck, Kristien
    De Lepeleire, Inge
    Shah, Jinesh
    Wagner, John A.
    Krishna, Rajesh
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (03): : 436 - 439
  • [22] Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein (vol 36, pg 994, 2016)
    Reyes-Soffer
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (05) : e51 - e51
  • [23] Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
    Krishna, Rajesh
    Garg, Amit
    Panebianco, Deborah
    Cote, Josee
    Bergman, Arthur J.
    Van Hoydonck, Pascale
    Laethem, Tine
    Van Dyck, Kristien
    Chen, Jingjing
    Chavez-Eng, Cynthia
    Archer, Laura
    Lutz, Ryan
    Hilliard, Deborah
    Snyder, Karen
    Jin, Bo
    Van Bortel, Luc
    Lasseter, Kenneth C.
    Al-Huniti, Nidal
    Dykstra, Kevin
    Gottesdiener, Keith
    Wagner, John A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (04) : 535 - 545
  • [24] Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
    Krishna, R.
    Bergman, A. J.
    Jin, B.
    Fallon, M.
    Cote, J.
    Van Hoydonck, P.
    Laethem, T.
    Gendrano, I. N., III
    Van Dyck, K.
    Hilliard, D.
    Laterza, O.
    Snyder, K.
    Chavez-Eng, C.
    Lutz, R.
    Chen, J.
    Bloomfield, D. M.
    De Smet, M.
    Van Bortel, L. M.
    Gutierrez, M.
    Al-Huniti, N.
    Dykstra, K.
    Gottesdiener, K. M.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (06) : 679 - 683
  • [25] Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin
    Krauss, Ronald M.
    Pinto, Cathy Anne
    Liu, Yang
    Johnson-Levonas, Amy O.
    Dansky, Hayes M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (01) : 93 - 102
  • [26] Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
    Johns, Douglas G.
    Wang, Sheng-Ping
    Rosa, Raymond
    Hubert, James
    Xu, Suoyu
    Chen, Ying
    Bateman, Thomas
    Blaustein, Robert O.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (06):
  • [27] Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page, Michael M.
    Hooper, Amanda J.
    Burnett, John R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (02) : 275 - 281
  • [28] Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia
    Menno Vergeer
    John JP Kastelein
    Nature Clinical Practice Cardiovascular Medicine, 2008, 5 : 302 - 303
  • [29] Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia
    Vergeer, Menno
    Kastelein, John J. P.
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2008, 5 (06): : 302 - 303
  • [30] A molecular dynamics investigation on the inhibition mechanism of cholesteryl ester transfer protein by Anacetrapib
    Mostafa Jamalan
    Majid Zeinali
    Mohammad Ali Ghaffari
    Medicinal Chemistry Research, 2016, 25 : 62 - 69
12345